Canagliflozin Anhydrous
The anhydrous form of canagliflozin, an SGLT2 inhibitor used for blood sugar management in type 2 diabetes with additional cardiovascular and renal benefits. This non-hydrated salt form is used in specific pharmaceutical formulations for stability. It shares the same mechanism and clinical profile as the standard canagliflozin formulation.
Peso molecular
444,5000 g/mol
LogP
3,20
TPSA
118,00 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
Molecular Formula
C24H25FO5S
HBD / HBA
4 / 7
Enlaces Rotables
5
Átomos Pesados
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The anhydrous form of canagliflozin, an SGLT2 inhibitor used for blood sugar management in type 2 diabetes with additional cardiovascular and renal benefits. This non-hydrated salt form is used in specific pharmaceutical formulations for stability. It shares the same mechanism and clinical profile as the standard canagliflozin formulation.
Selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood glucose levels independently of insulin secretion.
Yes, Canagliflozin Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2048484. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24812758. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="canagliflozin-anhydrous"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/canagliflozin-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/canagliflozin-anhydrous/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/canagliflozin-anhydrous/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="canagliflozin-anhydrous"></drugfyi-drug>